|
www.aurobindo.com |
|
|
Hyderabad, 14th July, 2005 |
|
|
|
CANADIAN AUTHORITY APPROVES
AUROBINDO'S FACILITIES |
|
|
|
Aurobindo Pharma Limited has achieved another
important milestone by getting Canadian
regulatory authority’s compliance for Unit III
for oral solid dosage forms and Unit VI for
sterile and non-sterile cephalosporin dosage
forms. Health Canada has approved the
aforementioned sites. |
|
Both the units are state-of-the-art facilities,
and are built for the regulated markets.
|
|
Unit III at Hyderabad, India, is one of the key
formulation manufacturing facilities of
Aurobindo Pharma. Unit III has four production
blocks and is dedicated to products other than
cephalosporins/penicillins oral dosage
formulations. Unit III is also approved by US
FDA, South African MCC, Brazilian ANVISA and UK
MHRA (previously known as UK MCA). In addition,
it holds ISO and approvals from several other
countries. |
|
Unit VI is situated in an 18-acre area, and
comprises 5 manufacturing blocks. Unit VI oral
dosage formulations is also approved by US FDA,
MCC - South Africa, Brazilian ANVISA and many
other regulatory agencies apart from Canadian
authority and is located near Hyderabad, Andhra
Pradesh. |
|
|
|
About Aurobindo Pharma Limited |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company has
received approvals for several facilities from
leading regulatory agencies like US FDA, UK MHRA,
WHO, Health Canada, MCC South Africa. The
company’s robust product portfolio is spread
over 6 major therapeutic/product areas
encompassing (Antibiotics, Anti-Retrovirals,
CVS, CNS, Gastroenterologicals, and Anti-Allergics)
around 65 APIs in the non-antibiotics and 55
APIs in the antibiotic segment. The Company is
marketing these products globally, in over 100
countries. |
|
|
|
|
|
PRESS
ROOM
